Rockland Trust Co. Grows Holdings in Edwards Lifesciences Co. (NYSE:EW)

Rockland Trust Co. boosted its position in Edwards Lifesciences Co. (NYSE:EW) by 8.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 4,353 shares of the medical research company’s stock after purchasing an additional 334 shares during the period. Rockland Trust Co.’s holdings in Edwards Lifesciences were worth $322,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at $32,000. Avior Wealth Management LLC increased its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $40,000. Finally, JFS Wealth Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,500 shares of company stock valued at $2,160,800. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $70.29 on Thursday. The stock has a market cap of $41.46 billion, a price-to-earnings ratio of 10.14, a PEG ratio of 3.61 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $71.82 and a 200 day simple moving average of $71.62. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 earnings per share. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of research analyst reports. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Barclays lifted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Citigroup increased their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Stifel Nicolaus boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Sixteen analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.